US20030177530A1 - (1 -> 3, 1 -> 4)-beta-glucanase of enhanced stability - Google Patents
(1 -> 3, 1 -> 4)-beta-glucanase of enhanced stability Download PDFInfo
- Publication number
- US20030177530A1 US20030177530A1 US09/785,246 US78524601A US2003177530A1 US 20030177530 A1 US20030177530 A1 US 20030177530A1 US 78524601 A US78524601 A US 78524601A US 2003177530 A1 US2003177530 A1 US 2003177530A1
- Authority
- US
- United States
- Prior art keywords
- gly
- ala
- arg
- glucanase
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004190 Enzymes Human genes 0.000 claims abstract description 93
- 108090000790 Enzymes Proteins 0.000 claims abstract description 93
- 235000013339 cereals Nutrition 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 22
- 150000002500 ions Chemical class 0.000 claims abstract description 16
- 150000001413 amino acids Chemical group 0.000 claims abstract description 15
- 235000001014 amino acid Nutrition 0.000 claims abstract description 12
- 238000006467 substitution reaction Methods 0.000 claims abstract description 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 7
- 230000036252 glycation Effects 0.000 claims abstract description 4
- 235000018417 cysteine Nutrition 0.000 claims abstract description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 241000209219 Hordeum Species 0.000 claims description 37
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 35
- 108010044467 Isoenzymes Proteins 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 235000018102 proteins Nutrition 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 15
- 241000196324 Embryophyta Species 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 14
- XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 238000004890 malting Methods 0.000 claims description 10
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 claims description 9
- 108010062796 arginyllysine Proteins 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 claims description 7
- 108010047495 alanylglycine Proteins 0.000 claims description 7
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 claims description 5
- 108010047857 aspartylglycine Proteins 0.000 claims description 5
- 230000003197 catalytic effect Effects 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 claims description 4
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 claims description 4
- 229940098396 barley grain Drugs 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- JSLGXODUIAFWCF-WDSKDSINSA-N Arg-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O JSLGXODUIAFWCF-WDSKDSINSA-N 0.000 claims description 3
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 claims description 3
- IWIANZLCJVYEFX-RYUDHWBXSA-N Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 IWIANZLCJVYEFX-RYUDHWBXSA-N 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 claims description 2
- NTQDELBZOMWXRS-IWGUZYHVSA-N Asp-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O NTQDELBZOMWXRS-IWGUZYHVSA-N 0.000 claims description 2
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 claims description 2
- JSIQVRIXMINMTA-ZDLURKLDSA-N Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O JSIQVRIXMINMTA-ZDLURKLDSA-N 0.000 claims description 2
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 108010060035 arginylproline Proteins 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 235000009973 maize Nutrition 0.000 claims description 2
- 108010029020 prolylglycine Proteins 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 claims 2
- GSMPSRPMQQDRIB-WHFBIAKZSA-N Asp-Gln Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O GSMPSRPMQQDRIB-WHFBIAKZSA-N 0.000 claims 2
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 claims 1
- PMGDADKJMCOXHX-BQBZGAKWSA-N Arg-Gln Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PMGDADKJMCOXHX-BQBZGAKWSA-N 0.000 claims 1
- BNODVYXZAAXSHW-IUCAKERBSA-N Arg-His Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 BNODVYXZAAXSHW-IUCAKERBSA-N 0.000 claims 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 claims 1
- XNSKSTRGQIPTSE-ACZMJKKPSA-N Arg-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O XNSKSTRGQIPTSE-ACZMJKKPSA-N 0.000 claims 1
- SJUXYGVRSGTPMC-IMJSIDKUSA-N Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O SJUXYGVRSGTPMC-IMJSIDKUSA-N 0.000 claims 1
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 claims 1
- LSPKYLAFTPBWIL-BYPYZUCNSA-N Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(O)=O LSPKYLAFTPBWIL-BYPYZUCNSA-N 0.000 claims 1
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 claims 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 claims 1
- IGRMTQMIDNDFAA-UWVGGRQHSA-N Lys-His Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IGRMTQMIDNDFAA-UWVGGRQHSA-N 0.000 claims 1
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 claims 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 claims 1
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- AOLHUMAVONBBEZ-STQMWFEESA-N Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AOLHUMAVONBBEZ-STQMWFEESA-N 0.000 claims 1
- 108010008355 arginyl-glutamine Proteins 0.000 claims 1
- 108010092854 aspartyllysine Proteins 0.000 claims 1
- 108010061238 threonyl-glycine Proteins 0.000 claims 1
- 108010051110 tyrosyl-lysine Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 230000001965 increasing effect Effects 0.000 abstract description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract description 2
- 235000004279 alanine Nutrition 0.000 abstract description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 4
- 239000004471 Glycine Substances 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 description 74
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 description 25
- 229920002498 Beta-glucan Polymers 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 9
- 101100282617 Bovine herpesvirus 1.1 (strain Cooper) gC gene Proteins 0.000 description 8
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 3
- 238000013124 brewing process Methods 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000005360 mashing Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- -1 Glu ion Chemical class 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- MOWBWPSGCTXGKR-UHFFFAOYSA-N [CH2+][C-3]([CH2+])[CH2+] Chemical compound [CH2+][C-3]([CH2+])[CH2+] MOWBWPSGCTXGKR-UHFFFAOYSA-N 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000015246 common arrowhead Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
- 108010073032 Grain Proteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 101100401106 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) met-7 gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 108010050181 aleurone Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000009567 fermentative growth Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- STKYPAFSDFAEPH-LURJTMIESA-N glycylvaline Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000005036 potential barrier Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/14—Pretreatment of feeding-stuffs with enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/244—Endo-1,3(4)-beta-glucanase (3.2.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2448—Licheninase (3.2.1.73)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01006—Endo-1,3(4)-beta-glucanase (3.2.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01073—Licheninase (3.2.1.73)
Definitions
- Barley quality encompasses a range of physical and chemical attributes, depending on whether the grain is to be used in the preparation of malt for brewing purposes, in the formulation of stockfeed, or as a component of human foods.
- specifications of barley quality are tailored primarily for the malting and brewing industries, in which germinated barley (malt) is the principal raw material.
- the quality specifications include such parameters as grain size, dormancy, malt extract, grain protein content, development of enzymes for starch degradation in malt and (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucan content.
- Malt extract is a widely-used quality indicator. It is an estimate of the percentage of malted grain that can be extracted with hot water.
- Malt extract values are influenced both by the composition of the ungerminated barley and by the speed and extent of endosperm modification during malting. Given the central role of cell walls as a potential barrier against the free diffusion of starch- and protein-degrading enzymes from the scutellum or from the aleurone to their substrates in cells of the starchy endosperm, it is not surprising that wall composition and the ability of the grain to rapidly produce enzymes that hydrolyse wall constituents are important determinants of malt extract values.
- the (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase potential of barley cultivars is also dependent on both genotype and environment, although environmental conditions during grain maturation appear to be particularly important in the development of the enzymes (Stuart et al, 1988).
- Monoclonal antibodies specific for barley (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanases have been used in enzyme-linked immunosorbent assays (ELISA) that may be useful for the quantitation of (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase levels in large numbers of barley lines generated in breeding programs (H ⁇ j et al, 1990).
- mutant barleys with altered (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucan content (Aastrup 1983; Molina-Cano et al, 1989) or (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase potential will be useful in future studies on the effects of these components on malting quality and may be valuable in breeding programmes.
- thermostable (1 ⁇ 3;1 ⁇ 4)- ⁇ -glucanase enzyme or to produce the (1 ⁇ 3;1 ⁇ 4)- ⁇ -glucanase enzymes exogenously as an additive to be used in the brewing process.
- (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase of amino acid sequence modified so as to provide enhanced thermostability and/or pH stability will have a variety of industrial uses, either by means of barley expressing the modified enzyme, or by addition of the modified enzyme to barley being processed.
- the invention provides a (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase of enhanced thermostability and/or pH stability.
- the invention provides an isolated DNA sequence encoding a (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase of enhanced thermostability and/or pH stability, and plasmids, expression vectors, and transgenic plants comprising said sequence.
- the expression host is E. coli or Saccharomyces cereviseae ; preferably the transgenic plant is barley. It will be clearly understood that barley grain from plants encoding the improved enzyme is within the scope of this invention.
- the invention provides a method selected from the group consisting of malting, brewing and stockfeed processing, comprising the step of
- the invention provides a composition for use in malting, brewing, or stockfeed processing, comprising the improved (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase of the invention, together with carriers acceptable for use in processing of beverages or of stockfeeds.
- FIG. 1 shows a stereo view of the alpha carbon trace of the polypeptide backbone of the EII and GII glucanase enzymes.
- the heavy lines represent the EII enzyme and the lighter lines represent the GII enzymes.
- the active site groove runs north to south, and the C- and N-termini are indicated, as are the two putative active site residues glutamic acids at residues 232 and 288 (using EII sequence numbers).
- FIG. 2 shows the sequence comparison of the EII (lower line) and GII (upper line) glucanase enzymes based on the 3-dimensional structure, with the sequence given using the three letter code for amino acids. Residue numbers at the start of each line are the sequence numbers of the two enzymes. The secondary structure elements of both enzymes are given above the GII sequence and below the EII sequence (see text for notation used in the description of the tertiary structure).
- ⁇ represents alpha helices
- ⁇ represents beta sheets
- a and B represent additional alpha helices and beta sheets to those of a typical ⁇ / ⁇ barrel.
- FIG. 3 is a schematic drawing of the (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase EII enzyme.
- the elements with arrow heads represent beta sheet structure and the elements with a curled tape coil represent alpha helices. Some of the smaller beta sheets are not drawn. Elsewhere the chain is represented as a rope. The black dots represent amino acid locations where thermostable mutants have been proposed (see text).
- FIG. 4 is a schematic drawing of the (1 ⁇ 3)- ⁇ -glucanase GII enzyme.
- the elements with arrow head represent beta sheet structure and the elements with a curled tape coil represent alpha helices. Some of the smaller beta sheets are not drawn. Elsewhere the chain is represented as a rope.
- the black dots represent amino acids locations around the active site groove which confer the specific activity of the enzymes. It is proposed to modify these amino acids to change the specificity of the GII enzyme into that of the EII enzyme.
- FIG. 5 shows a comparison between stability of (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase isoenzyme EII with that of (1 ⁇ 3)- ⁇ -glucanase isoenzyme GII at pH 3.5.
- FIG. 6 compares the stabilities of (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase isoenzymes EII with that of (1 ⁇ 3)- ⁇ -glucanase isoenzyme GII at 50°.
- FIG. 7 compares the stabilities of (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase isoenzyme EII with that of (1 ⁇ 3)- ⁇ -glucanase isoenzyme GII at increasing temperatures.
- FIG. 8 compares the stabilities of wildtype (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase isoenzyme EII and mutant H300P on heating for 15 minutes.
- FIG. 9 compares the stabilities of wildtype (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase isoenzyme EII and mutant H300P at 48° C.
- FIG. 10 compares the stabilities of wildtype (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase isoenzyme EII and mutant H300P during mashing at 55° C.
- the glucosyl residues are represented by G, (1 ⁇ 3)- and (1 ⁇ 4)- ⁇ -linkages by 3 and 4, respectively, and the reducing terminus (red) of the polysaccharide chain is indicated.
- the enzymes have an absolute requirement for adjacent (1 ⁇ 3)- and (1 ⁇ 4)- ⁇ -linked glucosyl residues in their substrates.
- the (1 ⁇ 3)- ⁇ -glucanases [EC 3.2.1.39] are able to hydrolyse the single (1 ⁇ 3)- ⁇ -linkages found in (1 ⁇ 3;1 ⁇ 4)- ⁇ -glucans, but can catalyse the hydrolysis of (1 ⁇ 3)- ⁇ -glucosyl linkages in (1 ⁇ 3)- ⁇ -glucans, as follows:
- thermostable or pH stable (1 ⁇ 3;1 ⁇ 4)- ⁇ -glucanase enzyme by transforming the (1 ⁇ 3)- ⁇ -glucanase into the (1 ⁇ 3;1 ⁇ 4)- ⁇ -glucanase. This is done by transferring elements of the catalytic site of the (1 ⁇ 3;1 ⁇ 4)- ⁇ -glucanase enzyme on to the (1 ⁇ 3)- ⁇ -glucanase enzyme.
- thermostable (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase and (1 ⁇ 3)- ⁇ -glucanase by creating cysteine pairs which can form disulphide bonds across the C and N terminals.
- Appendix 3 we have set out the 3-dimensional coordinates and mean thermal vibration parameters (isotropic B values) of the two enzymes, as determined from the crystallographic refinement of the X-ray diffraction data obtained from single crystals of each enzyme.
- the EII and GII glucanase structures have essentially identical ⁇ / ⁇ barrel folds (FIG. 1). Minor perturbations are found in the loops mainly at positions where there are sequence insertions and deletions.
- a sequence comparison is set out in FIG. 2.
- the active site groove which runs along the full length of the upper surface of the molecule perpendicular to the barrel axis, is almost identical in the central region of the groove, and different in detail towards the ends of the groove.
- the carboxylate groups of the two putative active site glutamates (Chen et al, 1993) are positioned in an identical way some 7 ⁇ apart.
- FIG. 2 elements of the secondary structure have been identified alongside the sequence alignment of the two enzymes.
- Minor ⁇ sheet and ⁇ helices are referred to as B i and A i , respectively if they appear after the strand ⁇ i and before ⁇ i+1 , and a further subscript a or b, if more than one occur.
- the active site groove runs north to south on the upper face of the molecule, as shown in FIGS. 3 and 4.
- the N-terminal starts under the molecule entering the east side of the barrel as ⁇ 1 and emerges on the upper surface and the heads back towards the bottom surface as ⁇ 1 (traversing the outside of the molecule) to meet ⁇ 2 , where this motif is repeated for strands ⁇ 2 to ⁇ 4 , building the upper half of a conventional ⁇ / ⁇ barrel (note that for the third ⁇ / ⁇ loop there are two helices).
- the lower half of the barrel has more elaborate secondary structural elements, not previously observed in other ⁇ / ⁇ barrel structures.
- This helix runs perpendicular to the groove axis and at the southern end of the groove and is supported by three two stranded antiparallel ⁇ sheet ‘fingers’ (B 5 on the upper surface, B 7 on the underneath surface and B 6 at the southern end of the groove) and three small helices (A 5 at the western side and A 6a and A 6a at the eastern side of the groove).
- This subdomain which forms a platform for the residues making up the lower half of the groove, is different in detail (possibly arising from the difference in specificity) between the EII and GII enzymes; for example the helix A 5 is missing in GII.
- the C-terminal strand consisting of some 30 residues, starts after the strand ⁇ 8 , and has an unusual turn which involves a cis peptide bond between residues Phe 275 and Ala 276 (a cis proline could not accommodate this type of turn). This turn allows the loop of residues from 276 to 286 to position the glutamate at 288, which is in a small helical turn ⁇ 8 , at the appropriate orientation to act as a catalytic acid group.
- the C-terminal strand finds its way down to the underside of the molecule between the helices ⁇ 1 and ⁇ 7 to within 4.2 ⁇ from the N-terminus.
- glucanase GII In order to observe which amino acids in the substrate-binding groove contacted the substrate, the structure of glucanase GII was determined after soaking crystals with 1 ⁇ 3 linked oligosaccharides. Three sites were found where glucose units of monomer or disaccharides bind to the protein The coordinates of these sites are listed in Appendix 2. This establishes the orientation of the substrate within the groove, and that some of the proposed changes to GII are important for substrate binding.
- glycines have been replaced by prolines or alanines in helices (Matthews et al, 1987) in order to stiffen the amino acid chain and reduce the entropy of the unfolded protein.
- Negatively charged residues have been attached to the N-termini of helices to stabilise them (Nicholson et al, 1988, Eijsink et al, 1992). Ion pairs have been introduced to increase the binding energy of the folded protein, and lysines changed. to arginines to prevent glycation and improve stability (Mrabet et al, 1992) by increasing the hydrogen-bonding with other parts of the protein.
- EI and EII refer to the isozymes of (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase and GI to GVI refer to the isozymes of the (1 ⁇ 3)- ⁇ -glucanase (Xu et al, 1992). The location of these substitutions are shown on FIG. 3.
- the mutation is described using the following notation: eg. the mutation Ala 14 Ser represents the mutation of the Alanine residue to a Serine at position 14 in the amino acid sequence (FIG. 3).
- the conventional 3 letter code for amino acids is used.
- FIG. 4 is a schematic drawing of the GII enzyme structure showing locations of the proposed mutations.
- Construction of the proposed mutant glucanases may be effected using the polymerase chain reaction (PCR)-based megaprimer method (Sarkar & Sommers, 1990), and single site mutants of the isozymes EI and EII have already been produced in this way by one of us (Doan and Fincher, 1992). Briefly, for each site mutant or short series of adjacent mutations one oligonucleotide is synthesised which contains the complementary sequence required for the mutation(s) and sufficient flanking regions to anneal to the wild type cDNA. This oligonucleotide is extended against the cDNA template with a DNA polymerase.
- PCR polymerase chain reaction
- PCR is used to amplify the mutant section of cDNA, and then this is inserted back into the plasmid containing the original cDNA. For multiple mutations this process is repeated to produce the final construct.
- site directed mutagenesis kits based on the unique site elimination method (Deng and Nickoloff, 1992) can be used.
- the proteins can then be expressed in E. coli (Wynn et al, 1992) using the plasmid ET or other vectors or in insect cells (e.g. Sf9 cells) using a Baculovirus system (Doan & Fincher, 1992).
- yeast would be a suitable host, and such an engineered yeast could be used directly in the brewing process.
- Site-directed mutagenesis was carried out by the unique restriction enzyme site elimination procedure using a U.S.E. Mutagenesis Kit (Pharmacia) with double-stranded plasmid DNA as a template.
- Appropriate mutagenic primers were designed to generate the mutations and were synthesized on a standard DNA synthesizer. All oligonucleotide primers were phosphorylated at their 5′-end before use, and the mutagenesis procedure was performed essentially as prescribed by the manufacturer. Mutants were confirmed by dideoxynucleotide sequencing using a Sequence version 2.0 sequencing Kit (U.S. Biochemical Co.).
- mutant cDNA inserts in the expression plasmid pMAL-c2 were transformed in E. coli DH5 ⁇ cells, and grown overnight at 37° C. in LB containing 0.2% glucose and 100 ⁇ g/ml ampicillin. Aliquots of the cell suspension were sub-cultured into the same medium and grown at 37° C. with vigorous shaking to an optical density at 600 nm of 0.5, induced for 3 h with 1 mM isophenyl- ⁇ -thiogalactoside and lysed with lysozyme treatment and freeze/thawing. After removal of cell debris by centrifugation, enzyme activity was measured either in the unpurified extract or following purification.
- Mutant enzymes were all purified by a single ion-exchange chromatography step employing a shallow salt gradient elution.
- the crude extract from 4 to 5 litre culture was diluted 10 fold with 15 mM Tris-HCl (pH 8.0) and applied at a flow rate of 2.5-3.0 ml/min to a DEAE-Sepharose column (5 ⁇ 21 cm) equilibrated with 12.5 mM Tris-HCl (pH 8.5). After exhaustive washing, bound proteins were eluted with a 1.9 litre linear 0-80 mM NaCl gradient at a flow rate of 2.0 ml/min. Fractions containing pure fusion protein were located by SDS-PAGE, pooled, concentrated and adjusted to 2.5 mM sodium acetate (pH 5.0) by ultrafiltration before clarification by centrifugation.
- (1 ⁇ 3,1 ⁇ 4)- ⁇ -Glucanase activity was measured viscometrically at 40° C., using 5 mg/ml barley (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucan in 50 mM sodium acetate pH 5.0 as substrate.
- a unit of activity is defined as the amount of enzyme causing an increase of 1.0 in the reciprocal specific viscosity ( ⁇ 1/ ⁇ sp ) per minute.
- Specific activity is expressed as the activity per mg protein.
- the cDNA encoding (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase isoenzyme EII was subjected to site-directed mutagenesis using the unique site elimination method (Deng and Nickoloff, 1992), to generate mutant H300P.
- the mutagenesis procedure was performed using a modified pET-3a vector containing the wild type (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase isoenzyme EII cDNA as a template, which enables the rapid purification of expressed foreign proteins using a nickel-based affinity resin (Hochuli et al, 1987).
- the expressed mutant H300P showed an increase in the T 50 value (the temperature at which only 50% of the initial activity remains) of approximately 3.8° C., after heating for 15 minutes at various temperatures. This is illustrated in FIG. 8.
- thermostability was provided by following the residual activity (A t ) of wild type isoenzyme EII and the corresponding mutant H300P over time at 48° C. The results are shown in FIG. 9. Finally, as a further indication of increased thermostability in a commercial context, activity of the wild type and mutant (1 ⁇ 3,1 ⁇ 4)- ⁇ -glucanase isoenzyme EII was measured over time in a simulated mashing experiment at 55° C. Briefly, mashing conditions were simulated by stirring malted, dried barley grain in water at 55° C.
- Met 7 Val as GI GII GIII allow loop 7-12 to pack tighter against C-terminus Ala 9 Gly as GII GIII GV GVI, allow loop 7-12 to pack tighter against C-terminus Ala 15 Pro as GIII GVI Met 21 Leu as GI-GVI, prevent close contact with Met 298 (or Lys) Phe 22 Tyr as GI-GVI, buried H-bond with Val 30 Asn 25 Lys as GI-GIV, cover hydrophobic patch Gly 26 Asn as GV, GVI, rigidify helix capping residue Gly 240 Ala rigidify loop Asn 279 Asp stronger H-bonds Ser 285 Pro rigidify loop Val 287 Pro rigidify loop Asn 290 His as GI GIV, His would pack tighter Phe 294 Tyr could H-bond to Asn 25 OD1 Asn 297 Asp as GI GII GVI, tighter H-bond in loop Met 298 Gly Main chain torsion angles suit Gly Val 301 Ala as
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
A modified cereal (1→3,1→4)-β-glucanase is produced by the method of single point substitution in a native cereal (1→3,1→4)-β-glucanase enzyme, whereby the substitution:
a) maintains enzyme specificity by conserving the active site groove of the native cereal (1→3,1→4)-β-glucanase enzyme; and
b) effects increased thermostability over the native cereal (1→3,1→4)-β-glucanase enzyme by:
i) replacing glycine by proline or alanine in helices of the cereal (1→3,1→4)-β-glucanase enzyme, in order to stiffen the enzyme amino acid chain and reduce entropy of the unfolded enzyme;
ii) attaching negatively charged residues to N-termini of helices in the native cereal (1→3,1→4)-β-glucanase enzyme;
iii) introducing ion pairs into the native cereal (1→3,1→4)-β-glucanase enzyme, to increase binding energy in the folded enzyme;
iv) replacing lysine by arginine in the cereal (1→3,1→4)-β-glucanase enzyme, and thereby preventing lysine glycation and increasing hydrogen bonding with other parts of the enzyme;
v) replacing, by glycine, an amino acid in the native cereal (1→3,1→4)-β-glucanase enzyme in which the main chain torsion angle about the N and Cα atoms is greater than 0°; or
vi) creating cysteine pairs in the native cereal (1→3,1→4)-β-glucanase enzyme which can form disulphide bonds across the C and N terminals.
Description
- Barley quality encompasses a range of physical and chemical attributes, depending on whether the grain is to be used in the preparation of malt for brewing purposes, in the formulation of stockfeed, or as a component of human foods. Currently, specifications of barley quality are tailored primarily for the malting and brewing industries, in which germinated barley (malt) is the principal raw material. The quality specifications include such parameters as grain size, dormancy, malt extract, grain protein content, development of enzymes for starch degradation in malt and (1→3,1→4)-β-glucan content. Malt extract is a widely-used quality indicator. It is an estimate of the percentage of malted grain that can be extracted with hot water. Barley breeders and growers strive to produce grain with high malt extract values, because greater extract percentages provide higher levels of materials for subsequent fermentative growth by yeast during brewing. Malt extract values are influenced both by the composition of the ungerminated barley and by the speed and extent of endosperm modification during malting. Given the central role of cell walls as a potential barrier against the free diffusion of starch- and protein-degrading enzymes from the scutellum or from the aleurone to their substrates in cells of the starchy endosperm, it is not surprising that wall composition and the ability of the grain to rapidly produce enzymes that hydrolyse wall constituents are important determinants of malt extract values.
- The major constituents of endosperm cell walls of barley are the (1→3,1→4)-β-glucans, which account for approximately 70% by weight of the walls (Fincher, 1975). In the germinating grain (1→3,1→4)-β-glucanases function to depolymerise (1→3,1→4)-β-glucans of cell walls during endosperm mobilisation.
- Total (1→3,1→4)-β-glucan in ungerminated barley grain is not highly correlated with malt extract (Henry 1986; Stuart et al, 1988). However, the residual (1→3,1→4)-β-glucan in malted barley is highly correlated, in a negative sense, with malt extract (Bourne et al, 1982; Henry 1986; Stuart et al, 1988), and this residual polysaccharide reflects a combination of the initial (1→3,1→4)-β-glucan levels in the barley and, more importantly, the capacity of the grain to rapidly produce high levels of (1→3,1→4)-β-glucanase during malting (Stuart et al, 1988). The (1→3,1→4)-β-glucanase potential of barley cultivars is also dependent on both genotype and environment, although environmental conditions during grain maturation appear to be particularly important in the development of the enzymes (Stuart et al, 1988). Monoclonal antibodies specific for barley (1→3,1→4)-β-glucanases have been used in enzyme-linked immunosorbent assays (ELISA) that may be useful for the quantitation of (1→3,1→4)-β-glucanase levels in large numbers of barley lines generated in breeding programs (HØj et al, 1990). Furthermore, mutant barleys with altered (1→3,1→4)-β-glucan content (Aastrup 1983; Molina-Cano et al, 1989) or (1→3,1→4)-β-glucanase potential will be useful in future studies on the effects of these components on malting quality and may be valuable in breeding programmes.
- The ability of the (1→3;1→4)-β-glucanases [E.C. 3.2.1.73] to retain enzymic activity at elevated temperatures (thermostability) is of extreme importance during the utilization of barley in the malting and brewing industries. Malt quality, as measured by the ‘malt extract’ index, is highly dependent on the ability of the grain to rapidly synthesize high levels of the enzyme during germination (Stuart et al, 1988). High levels of (1→3;1→4)-β-glucanases are also desirable in the brewing process, where residual (1→3;1→4)-β-glucans in malt extracts can adversely effect wort and beer filtration due to their propensity to form aqueous solutions of high viscosity. These residuals can also contribute to the formation of certain hazes or precipitates at elevated ethanol concentrations or low temperatures in the final beer (Woodward and Fincher, 1983). The elevated temperatures used during commercial malting and brewing lead to rapid and extensive inactivation of these enzymes. The high temperatures (up to 85°) of commercial kilning processes destroy greater than 60% of the enzyme activity and much of the remaining enzyme is inactivated by the hot water used for malt extraction (Brunswick et al, 1987), Loi et al, 1987). It is therefore highly desirable to develop commercial strains of barley that express a thermostable (1→3;1→4)-β-glucanase enzyme, or to produce the (1→3;1→4)-β-glucanase enzymes exogenously as an additive to be used in the brewing process.
- Barley (1→3;1→4)-β-glucans also pose problems in the stockfeed industry. In poultry formulations prepared from cereal grains, (1→3;1→4)-β-glucans significantly raise the viscosity of the gut contents of chickens. This impairs digestion and slows growth rates, and results in sticky faecal droppings that make hygienic handling of eggs and carcases difficult (Fincher and Stone, 1986). This application would require the enzyme to be stable at a range of pHs, particularly in the pH region of the foregut. It would also be an advantage for the enzyme to be sufficiently thermostable to withstand the steam pelleting processes widely used in stockfeed manufacture.
- Thus it is envisaged that (1→3,1→4)-β-glucanase of amino acid sequence modified so as to provide enhanced thermostability and/or pH stability will have a variety of industrial uses, either by means of barley expressing the modified enzyme, or by addition of the modified enzyme to barley being processed.
- There has been considerable interest in inserting (1→3,1→4)-β-glucanase genes into brewing yeasts, in the expectation that low level, constitutive expression would lead to the secretion of active enzyme and the depolymerisation of residual (1→3,1→4)-β-glucan during fermentation (Hinchliffe, 1988). A barley (1→3,1→4)-β-glucanase cDNA (Fincher et al, 1986) fused with a mouse α-amylase signal peptide is expressed and secreted from yeast under the direction of the yeast alcohol dehydrogenase I gene promoter (Jackson et al, 1986). Although the gene for isoenzyme EII has not yet been isolated, the availability of almost full length CDNA for use as a probe means that such isolation can readily be carried out using conventional methods.
- We have now determined the three dimensional structure of (1→3,1→4)-β-glucanase isoenzyme EII and (1→3)-β-glucanase isgenzyme GII (E.C.3.2.1.39), and have identified regions of the structures of these enzymes which are candidates for modification in order to provide enhanced thermal and pH stability, as well as suitable point mutations for achieving such stabilisation. We have found that the 3-dimensional structures of these two enzymes, which share only 50% sequence homology, are remarkably similar in their structural framework, and that their active sites are also surprisingly similar, despite the difference in substrate specificity.
- According to a first aspect, the invention provides a (1→3,1→4)-β-glucanase of enhanced thermostability and/or pH stability.
- In a second aspect, the invention provides an isolated DNA sequence encoding a (1→3,1→4)-β-glucanase of enhanced thermostability and/or pH stability, and plasmids, expression vectors, and transgenic plants comprising said sequence. Preferably the expression host isE. coli or Saccharomyces cereviseae; preferably the transgenic plant is barley. It will be clearly understood that barley grain from plants encoding the improved enzyme is within the scope of this invention.
- In a third aspect, the invention provides a method selected from the group consisting of malting, brewing and stockfeed processing, comprising the step of
- a) using barley expressing the (1→3,1→4)-β-glucanase of this invention as a starting material, or
- b) adding (1→3,1→4)-β-glucanase of this invention to a grain to be processed.
- In a fourth aspect, the invention provides a composition for use in malting, brewing, or stockfeed processing, comprising the improved (1→3,1→4)-β-glucanase of the invention, together with carriers acceptable for use in processing of beverages or of stockfeeds.
- The invention will now be described in detail by way of reference only to the following non-limiting examples, and to the figures, in which
- FIG. 1 shows a stereo view of the alpha carbon trace of the polypeptide backbone of the EII and GII glucanase enzymes. The heavy lines represent the EII enzyme and the lighter lines represent the GII enzymes. The active site groove runs north to south, and the C- and N-termini are indicated, as are the two putative active site residues glutamic acids at residues 232 and 288 (using EII sequence numbers).
- FIG. 2 shows the sequence comparison of the EII (lower line) and GII (upper line) glucanase enzymes based on the 3-dimensional structure, with the sequence given using the three letter code for amino acids. Residue numbers at the start of each line are the sequence numbers of the two enzymes. The secondary structure elements of both enzymes are given above the GII sequence and below the EII sequence (see text for notation used in the description of the tertiary structure).
- α represents alpha helices; β represents beta sheets; A and B represent additional alpha helices and beta sheets to those of a typical α/β barrel.
- FIG. 3 is a schematic drawing of the (1→3,1→4)-β-glucanase EII enzyme. The elements with arrow heads represent beta sheet structure and the elements with a curled tape coil represent alpha helices. Some of the smaller beta sheets are not drawn. Elsewhere the chain is represented as a rope. The black dots represent amino acid locations where thermostable mutants have been proposed (see text).
- FIG. 4 is a schematic drawing of the (1→3)-β-glucanase GII enzyme. The elements with arrow head represent beta sheet structure and the elements with a curled tape coil represent alpha helices. Some of the smaller beta sheets are not drawn. Elsewhere the chain is represented as a rope. The black dots represent amino acids locations around the active site groove which confer the specific activity of the enzymes. It is proposed to modify these amino acids to change the specificity of the GII enzyme into that of the EII enzyme.
- FIG. 5 shows a comparison between stability of (1→3,1→4)-β-glucanase isoenzyme EII with that of (1→3)-β-glucanase isoenzyme GII at pH 3.5.
- FIG. 6 compares the stabilities of (1→3,1→4)-β-glucanase isoenzymes EII with that of (1→3)-β-glucanase isoenzyme GII at 50°.
- FIG. 7 compares the stabilities of (1→3,1→4)-β-glucanase isoenzyme EII with that of (1→3)-β-glucanase isoenzyme GII at increasing temperatures.
- FIG. 8 compares the stabilities of wildtype (1→3,1→4)-β-glucanase isoenzyme EII and mutant H300P on heating for 15 minutes.
- FIG. 9 compares the stabilities of wildtype (1→3,1→4)-β-glucanase isoenzyme EII and mutant H300P at 48° C.
- FIG. 10 compares the stabilities of wildtype (1→3,1→4)-β-glucanase isoenzyme EII and mutant H300P during mashing at 55° C.
-
- The glucosyl residues are represented by G, (1→3)- and (1→4)-β-linkages by 3 and 4, respectively, and the reducing terminus (red) of the polysaccharide chain is indicated. Thus the enzymes have an absolute requirement for adjacent (1→3)- and (1→4)-β-linked glucosyl residues in their substrates. The (1→3)-β-glucanases [EC 3.2.1.39] are able to hydrolyse the single (1→3)-β-linkages found in (1→3;1→4)-β-glucans, but can catalyse the hydrolysis of (1→3)-β-glucosyl linkages in (1→3)-β-glucans, as follows:
- Arrows indicate the hydrolysis of (1→3)-β-linkages between glucosyl residues (G).
- Furthermore it is known that the (1→3)-β-glucanase isoenzyme GII is more thermostable, pH stable and protease resistant than the (1→3;1→4)-β-glucanase EII enzyme. Thus using the three dimensional structures of these enzymes, we can create more stable forms of the (1→3;1→4)-β-glucanase by the following methods:
- (a) transferring the structural elements that generate the heat stability of the (1→3)-β-glucanase, on to the (1→3;1→4)-β-glucanase.
- (b) modifying the (1→3;1→4)-β-glucanase using general principles of protein structure and stability (Matthews, 1987).
- (c) engineering a thermostable or pH stable (1→3;1→4)-β-glucanase enzyme by transforming the (1→3)-β-glucanase into the (1→3;1→4)-β-glucanase. This is done by transferring elements of the catalytic site of the (1→3;1→4)-β-glucanase enzyme on to the (1→3)-β-glucanase enzyme.
- (d) engineering a thermostable (1→3,1→4)-β-glucanase and (1→3)-β-glucanase by creating cysteine pairs which can form disulphide bonds across the C and N terminals.
- A combination of two or more of these methods may be used.
- For each of these methods knowledge of the protein structures is an important prerequisite. This knowledge enables us to separate differences between the two enzymes which govern substrate specificity from those for thermal and pH stability. It also enables us to predict which kind of changes to the sequence which will enhance the stability of the secondary structure elements. Random mutagenesis of glucanase genes will invariably reduce the stability of the protein by disrupting its structure, or may cause inactivation of the enzyme. This is due to the inability of current methods to predict protein folding and catalytic activity from amino acid sequence information alone.
- We have determined the 3-dimensional structure of (1→3;1→4)-β-glucanase isoenzyme EII (hereafter called EII) and (1→3)-β-glucanase isoenzyme GII (hereafter called GII) to Sigh resolution (2.2 Å) by X-ray crystallographic techniques described by Blundell and Johnson (1979).
- In Appendix 3 we have set out the 3-dimensional coordinates and mean thermal vibration parameters (isotropic B values) of the two enzymes, as determined from the crystallographic refinement of the X-ray diffraction data obtained from single crystals of each enzyme.
- The EII and GII glucanase structures have essentially identical α/β barrel folds (FIG. 1). Minor perturbations are found in the loops mainly at positions where there are sequence insertions and deletions. A sequence comparison is set out in FIG. 2. The active site groove, which runs along the full length of the upper surface of the molecule perpendicular to the barrel axis, is almost identical in the central region of the groove, and different in detail towards the ends of the groove. The carboxylate groups of the two putative active site glutamates (Chen et al, 1993) are positioned in an identical way some 7 Å apart. Also around these residues are a ring of residues which are totally conserved in all plant (1→3)-β-glucanases known (Xu et al, 1992 and sequences from the Genbank database). Details of the structure, which is a novel type of α/β barrel are given below.
- In FIG. 2 elements of the secondary structure have been identified alongside the sequence alignment of the two enzymes. We shall refer to the beta barrel strands as βi and the major (longest) helices connecting the beta strands as α1, where i goes from 1 to 8. Minor β sheet and α helices are referred to as Bi and Ai, respectively if they appear after the strand βi and before βi+1, and a further subscript a or b, if more than one occur.
- Looking at the glucanase tertiary structure from above, down the barrel axis (the long axis of the elliptical barrel running east west), the active site groove runs north to south on the upper face of the molecule, as shown in FIGS. 3 and 4.
- The N-terminal starts under the molecule entering the east side of the barrel as β1 and emerges on the upper surface and the heads back towards the bottom surface as α1 (traversing the outside of the molecule) to meet β2, where this motif is repeated for strands β2 to β4, building the upper half of a conventional α/β barrel (note that for the third α/β loop there are two helices).
- The lower half of the barrel has more elaborate secondary structural elements, not previously observed in other α/β barrel structures. There is what could be called a subdomain built around the helix α6. This helix runs perpendicular to the groove axis and at the southern end of the groove and is supported by three two stranded antiparallel β sheet ‘fingers’ (B5 on the upper surface, B7 on the underneath surface and B6 at the southern end of the groove) and three small helices (A5 at the western side and A6a and A6a at the eastern side of the groove). This subdomain, which forms a platform for the residues making up the lower half of the groove, is different in detail (possibly arising from the difference in specificity) between the EII and GII enzymes; for example the helix A5 is missing in GII.
- The C-terminal strand, consisting of some 30 residues, starts after the strand β8, and has an unusual turn which involves a cis peptide bond between residues Phe 275 and Ala 276 (a cis proline could not accommodate this type of turn). This turn allows the loop of residues from 276 to 286 to position the glutamate at 288, which is in a small helical turn α8, at the appropriate orientation to act as a catalytic acid group. The C-terminal strand then finds its way down to the underside of the molecule between the helices α1 and α7 to within 4.2 Å from the N-terminus.
- In order to observe which amino acids in the substrate-binding groove contacted the substrate, the structure of glucanase GII was determined after soaking crystals with 1→3 linked oligosaccharides. Three sites were found where glucose units of monomer or disaccharides bind to the protein The coordinates of these sites are listed in Appendix 2. This establishes the orientation of the substrate within the groove, and that some of the proposed changes to GII are important for substrate binding.
- The following amino acid changes are proposed for enhancing the thermostability of (1→3,1→4)-β-glucanase EII, based on the 3-dimensional structure of the EII and GII enzymes. Some of the changes proposed involve substituting the GII amino acids that could be responsible for stabilizing that protein. These substitutions are based on the principle that the proposed changes will not alter the specificity of the enzyme (leave the active site groove unaltered), and where changes would not lead to deleterious changes in the 3-dimensional structure of the protein. Where possible glycines have been replaced by prolines or alanines in helices (Matthews et al, 1987) in order to stiffen the amino acid chain and reduce the entropy of the unfolded protein. Negatively charged residues have been attached to the N-termini of helices to stabilise them (Nicholson et al, 1988, Eijsink et al, 1992). Ion pairs have been introduced to increase the binding energy of the folded protein, and lysines changed. to arginines to prevent glycation and improve stability (Mrabet et al, 1992) by increasing the hydrogen-bonding with other parts of the protein. EI and EII refer to the isozymes of (1→3,1→4)-β-glucanase and GI to GVI refer to the isozymes of the (1→3)-β-glucanase (Xu et al, 1992). The location of these substitutions are shown on FIG. 3. The mutation is described using the following notation: eg. the mutation Ala 14 Ser represents the mutation of the Alanine residue to a Serine at position 14 in the amino acid sequence (FIG. 3). The conventional 3 letter code for amino acids is used.
Mutation comments Ala 14 Ser as in GII, GV, GVI to stabilise helix α1 Ala 15 Arg as in GII, GIV, GV ion pair with Asp 36 at end of groove Thr 17 Asp as in GII to form ion pair with Met 298 Lys in GII Lys 23 Arg as in GI to GIV, H-bond to O46 Lys 28 Arg Asn 36 Asp as in GI, GII, GIV, GVI, EI, to stabilise helix α2, ibid Gly 44 Arg as in GI, GII, GV, GVI Gly 45 Asn as in GII, solvent exposed Gly 53 Asp as in GI, GII, GIII, GV, forms a stable ion pair with Arg 31 Gly 53 Glu Lys 74 Arg as in GI, GV Gln 78 Arg as in GI, GII Ala 79 Pro as in GI, GII, GVI, surface residue Lys 82 Arg Ala 95 Asp as in GIII, ion pair with Arg 128 at end of groove, Asn in GII Gly 97 Pro Phe 85 Tyr OH of Tyr H-bonds to O 76 Lys 107 Arg as in GI, GII, GIII, GIV Gly 111 Ala as in GII, helix residue Gly 119 Pro Lys 122 Arg conserved in all except GVI, H-bond to O 161 and O 120 Ser 128 Arg as in GI to GV Gly 133 Ala as in GII, on the lip of the groove, could have packing problems here with Thr 144 Gly 145 Asn different conformation in GII Gly 152 Thr as in GII, His 221 will clash with Thr so need to change His to Ala Pro 153 Asp as in GII, see below for ion pair Gln 156 Arg as in GII, need Pro 153 Asp for ion pair Asn 162 Gly Gly 185 Asn as in GII, stabilised by Asp 183 Ala 191 Pro as in GII, buried (near surface) Gly 193 Ala wrong dihedrals for a Pro Gly 199 Pro as in GI, GII has a different loop conformation solvated, so could be modified. Ala 200 GlyGly 202 Thr as in GII, H-bond to Thr 194 and Arg 197 space for Prohere. Gly 219 Glu as in GI to GVI, ion pair with Arg 265 might need Glu 266 Lys Lys 220 Arg as in GI H-bonds to O139 His 221 Ala as in GII, ibid Gly 223 Ala as in GII (buried) Ser 224 Pro as in GI to GV Lye 227 Arg as in GI, GIV, GV, ion pair with Glu 268 Gly 238 Ala as in GI, GII, GIV, GV, could clash with Asn 290 Gly 239 Gln as in GIII wrong dihedrals form a Pro Ala 242 Gly Gly 260 Glu ion pair with Arg 261 or Pro Pro 267 Arg as in GII Gly 268 Glu as in GII, could for ion pair with Arg 227 (peptide flipped wrt GII) Gly 286 Ala as in GII or Asp to stabilise helix α7 Gln 289 Arg as in GII, GIV, GV Met 298 Lys as in GI, GII, GIV, GV, ibid His 300 Pro as in GI to GV - Of the above proposed modification the following ion pairs have to be substituted at the same time.
Ala 15 Argand Asn 36 Asp Thr 17 Asp and Met 298 Lys Ala 95 Asp and Ser 128 Arg Pro 153 Asp and Gln 156 Arg Lys 227 Arg and Gly 268 Arg Gly 152 Thr and His 221 Ala - It will be clearly understood that, subject to this requirement for concurrent substitution of ion pairs, combinations of two or more of the proposed modifications may be used.
- An additional class of mutations is proposed in which the main chain torsion angle about the N and Cα atoms is greater than 0°. In this case a replacement by a Gly residue is energetically more favourable, particularly at the C terminal of an α-helix (Aurora et al., 1994). These mutations are:
Asn 162 Gly as in GI, GII, GV, GVI, EI, terminus of helix α5 Ala 200 Gly as in GIII, GIV, GV, GIV, main chain torsion angles Ala 242 Gly Main chain torsion angles Met 298 Gly Main chain torsion angles - As mentioned before the most noticeable feature of both the GII and EII enzymes is a deep groove across one face of the molecule. This appears to be the substrate binding site. Using structural information from both the GII and EII enzymes it is possible to determine which amino acid residues are likely to control substrate specificity. Furthermore, as these two enzymes are very similar in structure it is possible to graft the loops from one enzyme on to the more heat and pH stable framework of the other to change the specificity.
- We propose replacing the GII loops which form the sides and bottom of the cleft by the corresponding amino acids from the EII enzyme. These changes are as follows:
residue 8 Ile→Ser, residue 34 Phe→Ala, residue 208 Ala→Thr, residue 209 Met→Thr, residue 213 Val→Phe residue 128-137 Ile-Arg-Phe-Asp- (SEQ. ID NO:1) Glu-Val-Ala-Asn-Ser-Phe→ Val-Ser-Gln-Ala-Ile-Leu- Gly-Val-Phe-Ser, residue 171-179 Phe-Ala-Tyr-Arg- (SEQ. ID NO:2) Asp-Asn-Pro-Gly-Ser→ Leu-Ala-Trp-Ala-Tyr-Asn- Pro-Ser-Ala and residue 283-291 Thr-Gly-Asp-Ala- (SEQ. ID NO:3) Thr-Glu-Arg-Ser-Phe→ Asp-Ser-Gly-Val-Glu-Gln- Asn-Trp - Some or all of these changes are necessary. The skilled person will readily be able to test the effectiveness of the substitutions.
- Again combinations of two or more of these proposed modifications may be used.
- Doan and Fincher (1992) showed that relative to the EI enzyme, EII is more thermostable because of the carbohydrate at residue 190. We propose to introduce a carbohydrate attachment site into the modified GII enzyme to enhance the thermostability. The mutations required are 189-191 Gln-Pro-Gly→Asn-Ala-Ser
- FIG. 4 is a schematic drawing of the GII enzyme structure showing locations of the proposed mutations.
- Construction of the proposed mutant glucanases may be effected using the polymerase chain reaction (PCR)-based megaprimer method (Sarkar & Sommers, 1990), and single site mutants of the isozymes EI and EII have already been produced in this way by one of us (Doan and Fincher, 1992). Briefly, for each site mutant or short series of adjacent mutations one oligonucleotide is synthesised which contains the complementary sequence required for the mutation(s) and sufficient flanking regions to anneal to the wild type cDNA. This oligonucleotide is extended against the cDNA template with a DNA polymerase. PCR is used to amplify the mutant section of cDNA, and then this is inserted back into the plasmid containing the original cDNA. For multiple mutations this process is repeated to produce the final construct. Alternatively, commercially-available site directed mutagenesis kits based on the unique site elimination method (Deng and Nickoloff, 1992) can be used.
- We currently have the cDNAs for the EII and GII enzymes which form the starting points for the mutagenesis (Doan and Fincher, 1992; HØj et al, 1989). For the purposes of demonstrating improved stability or altered specificity of these enzymes and for production of the enzymes in quantity, the proteins can then be expressed inE. coli (Wynn et al, 1992) using the plasmid ET or other vectors or in insect cells (e.g. Sf9 cells) using a Baculovirus system (Doan & Fincher, 1992). A person skilled in the art will be aware of a variety of other suitable expression systems. For example, yeast would be a suitable host, and such an engineered yeast could be used directly in the brewing process. The availability of the gene encoding (1→3,1→4)-β-glucanase isoenzyme EI and near full-length cDNAs for isoenzymes EI and EII (Slakeski et al, 1990) presents an opportunity to accelerate or enhance (1→3,1→4)-β-glucanase development in germinated grain through gene technology. Increased enzyme activity might be achieved by several means, for example, by splicing more efficient promoters onto the gene, by altering the existing promoter to enhance expression levels, by the use of translational enhancers, or by increasing the copy number of the genes.
- Two more steps are required for the mutant enzymes to be incorporated into barley and expressed in a spatially and temporally appropriate manner. These are construction of a barley glucanase gene with the appropriate control of expression, and the insertion of the gene into a viable barley plant. The sequence the EII gene, including the promoter regions and the coding region and the signal peptide has been determined (Wolf, 1991). Thus for correct expression of the mutant glucanases we will replace a portion of this gene by the corresponding portion of a mutant cDNA using the above methods. It is expected that transformation of barley, that is to regenerate a fertile transgenic barley plant, will be possible in the near future. Foreign or manipulated DNA can be integrated into the barley genome in a stable form (Lazzeri et al, 1991) and fertile plants can be regenerated from single protoplasts (Jahne et al, 1991a, b). Among the cereals related to barley, rice can now be routinely transformed, and transformation of both wheat and maize has been reported. Methods for effecting transformation of monocotyledonous plants such as barley using biolistic techniques are widely used, and whole plants of transgenic barley have been grown. Barley has recently been transformed using the biolistic microprojectile gun procedure (Wan and Lemaux, 1994).
- i) Stability of GII and EII at pH 3.5
- (1→3)-β-glucanase isoenzyme GII (9.2 μg/ml) and (1→3,1→4)-β-glucanase isoenzyme EII (0.23 mg/ml) were incubated in 100 mM sodium acetate buffer at pH 3.5 in the presence of bovine serum albumin at 37° C. (0.5 mg/ml) Residual enzyme activities (At) were determined and compared to the initial activity at t=0 (Ao). The results are illustrated in FIG. 5. GII shows markedly greater stability with time at pH 3.5 than does EII. (Note: at pH 4.3 the enzymes differ only slightly in their stability and exhibit only minimal loss of activity; data not shown).
- ii) Stabilities of GII and EII at 50° C.
- (1→3)-β-glucanase isoenzyme GII (16 μg/ml) and (1→3;1→4)-β-glucanase isoenzyme EII (19 μg/ml) were incubated in 50 mm sodium acetate buffer at pH 5.0 in the presence of bovine serum albumin (1 mg/ml) at 50° C. Residual enzyme activities (At) were determined and compared to the initial activity at t=0 (Ao). The results are illustrated in FIG. 6. GII is very much more stable at 50° C. than is EII.
- iii) Stabilities of GII and EII at Increasing Temperatures
- (1→3)-β-glucanase isoenzyme GII (16 μg/ml) and (1→3;1→4)-β-glucanase isoenzyme EII (19 μg/ml) were incubated in 50 mM sodium acetate buffer at pH 5.0 at the indicated temperature for 15 min. Residual enzyme activities (At) were determined and compared to the initial activity at t=0) (Ao). The results are illustrated in FIG. 7. EII is stable only up to 40° C., while GII is stable up to 50° C.
- Of the possible mutations listed in Example 3, the following alterations were considered to be the most likely to improve stability. The alterations are based on:
1. creation of ion pairs: Gly 53 Asp Gly 53 Glu Thr 17 Asp; Met 298 Lys Ala 95 Asp; Ser 128 Arg 2. removal of potential glycation sites: Lys 122 Arg Lys 23 Arg Lys 74 Arg 3. reduction in entropy of unfolded state: Gly 44 Arg Gly 223 Ala Ala 79 Pro 4. hydrophobic effects: Phe 85 Tyr - Site-directed mutagenesis was carried out by the unique restriction enzyme site elimination procedure using a U.S.E. Mutagenesis Kit (Pharmacia) with double-stranded plasmid DNA as a template. Appropriate mutagenic primers were designed to generate the mutations and were synthesized on a standard DNA synthesizer. All oligonucleotide primers were phosphorylated at their 5′-end before use, and the mutagenesis procedure was performed essentially as prescribed by the manufacturer. Mutants were confirmed by dideoxynucleotide sequencing using a Sequence version 2.0 sequencing Kit (U.S. Biochemical Co.).
The following EII mutants were produced and confirmed by sequence analysis: Lys 74 Arg Gly 44 Arg Phe 85 Arg Gly 53 Glu Lys 122 Arg Lys 23 Arg Ala 79 Pro In addition, we have also made the following mutants: Gly 223 Ala Gly 53 Asp - The mutant cDNA inserts in the expression plasmid pMAL-c2 were transformed inE. coli DH5α cells, and grown overnight at 37° C. in LB containing 0.2% glucose and 100 μg/ml ampicillin. Aliquots of the cell suspension were sub-cultured into the same medium and grown at 37° C. with vigorous shaking to an optical density at 600 nm of 0.5, induced for 3 h with 1 mM isophenyl-β-thiogalactoside and lysed with lysozyme treatment and freeze/thawing. After removal of cell debris by centrifugation, enzyme activity was measured either in the unpurified extract or following purification.
- The following EII mutants have been expressed inE. coli and the expressed proteins have been confirmed to be of the correct size:
- Lys 122 Arg
-
Phe 85 Tyr - Gly 44 Arg
- For the purification of the wild-type enzyme, crude extract from 1 litre culture was diluted 10-fold with 15 mM Tris-Hcl buffer, pH 8.0 and applied at a flow rate of 2.5 ml/min to a DEAE-Sepharose Fast Flow (Pharmacia) column (3×11.5 cm) equilibrated with 25 mM Tris-HCl buffer, pH 8.0. After washing the column exhaustively, bound proteins were eluted with a linear 0-250 mM NaCl gradient in 1.2 litre equilibration buffer. Fractions containing significant enzyme activity were pooled, desalted and adjusted to 25 mM NaAc, pH 5.0. After exhaustive washing, bound proteins were eluted with a linear 0-200 mM NaCl gradient in 1 litre equilibration buffer. The fractions containing pure protein were pooled to give 5.0 mg active fusion protein.
- Mutant enzymes were all purified by a single ion-exchange chromatography step employing a shallow salt gradient elution. The crude extract from 4 to 5 litre culture was diluted 10 fold with 15 mM Tris-HCl (pH 8.0) and applied at a flow rate of 2.5-3.0 ml/min to a DEAE-Sepharose column (5×21 cm) equilibrated with 12.5 mM Tris-HCl (pH 8.5). After exhaustive washing, bound proteins were eluted with a 1.9 litre linear 0-80 mM NaCl gradient at a flow rate of 2.0 ml/min. Fractions containing pure fusion protein were located by SDS-PAGE, pooled, concentrated and adjusted to 2.5 mM sodium acetate (pH 5.0) by ultrafiltration before clarification by centrifugation.
- (1→3,1→4)-β-Glucanase activity was measured viscometrically at 40° C., using 5 mg/ml barley (1→3,1→4)-β-glucan in 50 mM sodium acetate pH 5.0 as substrate. A unit of activity is defined as the amount of enzyme causing an increase of 1.0 in the reciprocal specific viscosity (Δ1/ηsp) per minute. Specific activity is expressed as the activity per mg protein.
- The activities of the following mutant enzymes have been measured and compared with the activity of the expressed wild type enzyme:
Lys 122 Arg activity same as wild type Phe 85 Pyr activity approx. 70% of wild type Gly 44 Arg activity very low - Aliquots of wild type or mutant fusion proteins were diluted with 50 mM sodium acetate buffer, pH 5.5 and incubated at temperatures ranging from 40° C. to 60° C. for 15 min. Samples incubated at 0° C. were used as controls. Residual enzyme activity was determined viscometrically with 550 μl (1→3,1→4)-β-glucan substrate, as described for Example 10.
- References listed herein are identified on the following pages.
- It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.
- Stability of (1→3,1→4)-β-glucanase isoenzyme EII (mutant H300P)
- The cDNA encoding (1→3,1→4)-β-glucanase isoenzyme EII was subjected to site-directed mutagenesis using the unique site elimination method (Deng and Nickoloff, 1992), to generate mutant H300P. The mutagenesis procedure was performed using a modified pET-3a vector containing the wild type (1→3,1→4)-β-glucanase isoenzyme EII cDNA as a template, which enables the rapid purification of expressed foreign proteins using a nickel-based affinity resin (Hochuli et al, 1987). The expressed mutant H300P showed an increase in the T50 value (the temperature at which only 50% of the initial activity remains) of approximately 3.8° C., after heating for 15 minutes at various temperatures. This is illustrated in FIG. 8.
- An additional test for increased thermostability was provided by following the residual activity (At) of wild type isoenzyme EII and the corresponding mutant H300P over time at 48° C. The results are shown in FIG. 9. Finally, as a further indication of increased thermostability in a commercial context, activity of the wild type and mutant (1→3,1→4)-β-glucanase isoenzyme EII was measured over time in a simulated mashing experiment at 55° C. Briefly, mashing conditions were simulated by stirring malted, dried barley grain in water at 55° C. for 40 minutes to inactivate any endogenous (1→3,1→4)-β-glucanase activity, and then wild type or mutant H300P enzyme was added to the mash and residual activity (At) was monitored over time. The results are shown in FIG. 10.
-
Met 7 Val as GI GII GIII, allow loop 7-12 to pack tighter against C-terminus Ala 9 Gly as GII GIII GV GVI, allow loop 7-12 to pack tighter against C- terminus Ala 15 Pro as GIII GVI Met 21 Leu as GI-GVI, prevent close contact with Met 298 (or Lys) Phe 22 Tyr as GI-GVI, buried H-bond with Val 30Asn 25 Lys as GI-GIV, cover hydrophobic patch Gly 26 Asn as GV, GVI, rigidify helix capping residue Gly 240 Ala rigidify loop Asn 279 Asp stronger H-bonds Ser 285 Pro rigidify loop Val 287 Pro rigidify loop Asn 290 His as GI GIV, His would pack tighter Phe 294 Tyr could H-bond to Asn 25 OD1 Asn 297 Asp as GI GII GVI, tighter H-bond in loop Met 298 Gly Main chain torsion angles suit Gly Val 301 Ala as GI-GIII, change water structure 307 Asn extend C terminus to make a salt bridge with Lys 28 Ala 176 Arg and Gly 286 Asp ion pair Ser 237 Phe and Asn 279 Ser close packed bridge across or Trp C-terminal tail - As the N and C termini are close to each other it would be possible to tie down the C terminus by linking the ends together. The shortest linker with a structurally reasonable conformation is Ala-Ala-Gly (or Gly-Pro-Gly or combinations). As helix a6 and strand b7 are buried in the protein, new N and C termini at Val 226 and Gly 223 will not reduce the thermostability of the protein. Furthermore the new termini could form an ion pair.
- References
- Aastrup S. Carlsberg Res. Comnmun., 1983 48 307-316
- Aurora, R., Srinivasan, R., and Rose, G. D. Science, 1994 264 1126-1130
- Bamforth, C. W. Brewers Digest, 1983 57 22-27
- Blundell, T. L. and Johnson, L. N. Protein Crystallography, 1976, Academic Press, London
- Bourne, D. T., Powlessland, T. and Wheeler, R. E. j. Inst. Brew., 1982 88 371-375
- Brunswick,P., Manners, D. J. and Stark, J. R. J. Inst. Brew., 1987 93 181-186
- Chen, L., Fincher, G. B. and HØj, P. B. J. Biol. Chem., 1993 268, in press
- Deng, W. P. and Nickoloff, J. A. Analytical Biochemistry, 1992 200 81
- Doan, D. N. P. and Fincer, G. B. FEBS Lett, 1992 309 265-271
- Eijsink, V. G. H, Vriend, G., van den Burg, B., van der Zee, J. R. and Venema, G. Prot. Eng., 1992 5 165-170
- Fincher, G. B. J. Inst. Brewing, 1975 81 116-122
- Fincher, G. B., Lock, P. A., Morgan, M. M., Lingelbach, E., Wettenhall, R. E. H., Mercer, J. f. B., Brandt, A. and Thomsen, K. K. Proc. Natl. Acad. Sci. USA, 1986 83 2081-2085
- Fincher, G. B. and Stone, B. A. Adv. Cer. Sc. Techn., 1986 8 207-295
- Henry, R. J. J. Cereal Sci., 1986 4 269-277
- HØj, P. B., Hartman, D. J., Morrice, N. A., Doan, D. N. P. and Fincher, G. B. Plant Mol. Biol., 1989 13 31-42
- HØj, P. B., Hoogenraad, N. J., Hartman, D. J., Yanakena, H. and Fincher, G. B. J. Cereal Science, 1990 11 261-268
- Jahne, A., Lazzeri, P. A., Jager-Gussen, M. and Lorz, H. Theor. Appl. Genet, 1991 82 74-80
- Lazzeri, P. A., Brettschneider, R., Luhrs, R., and Lorz, H. Theor. Appl. Genet., 1991 81 437-444
- Loi, L., Barton, P. A. and Fincher, G. B. J. Cer. Sci., 1987 5 45-50
- Matthews, B. W. Biochemistry, 1987 26 6885-6888
- Matthews, B. W., Nicholson, H., Becktel, W. J. Proc. Natl. Acad. Sci. U.S.A., 1987 84 6663-6667
- Mrabet, N. T. et al Biochem., 1992 31 2239-2253
- Nicholson, H., Becktel, W. J., Matthews, B. W. Nature (London), 1988 336 651-656
- Powell, W., Caligari, P. D. S., Swanston, J. S. and Jinks, J. L. Theoretical and Applied Genetics, 1989 71 461-466
- Sarkar, G and Sommers, S. S. BioTequniques, 1990 4 404-407
- Slakeski, N., Baulcombe, D. C., Devos, R. M. Ahluwalia, B., Doan, D. N. P. and Fincher G. B. Mol. Gen. Genet., 1990 224 437-449
- Stuart, I. M., Loi, L. and Fincher, G. B. J. Cer. Sci. 1988 7 61-71
- Wan, Y and Lemaux, P. G. Plant Physiology, 1994 104 37-48
- Wolf, N. Plant Physiol., 1991 96 1382-1384
- Woodward, J. R. and Fincher, G. B. Brewers Digest, 1983 58 28-32
- Wynn, R. M, Davie, J. R., Cox, R. P. and Chuang, D. T. J. Bio. Chem. 1992 267 12400-12403
-
-
1 8 10 amino acids amino acid <Unknown> linear protein 1 Ile Arg Phe Asp Glu Val Ala Asn Ser Phe 1 5 10 10 amino acids amino acid <Unknown> linear protein 2 Val Ser Gln Ala Ile Leu Gly Val Phe Ser 1 5 10 9 amino acids amino acid <Unknown> linear protein 3 Phe Ala Tyr Arg Asp Asn Pro Gly Ser 1 5 9 amino acids amino acid <Unknown> linear protein 4 Leu Ala Trp Ala Tyr Asn Pro Ser Ala 1 5 9 amino acids amino acid <Unknown> linear protein 5 Thr Gly Asp Ala Thr Glu Arg Ser Phe 1 5 8 amino acids amino acid <Unknown> linear protein 6 Asp Ser Gly Val Glu Gln Asn Trp 1 5 306 amino acids amino acid <Unknown> linear protein 7 Ile Gly Val Cys Tyr Gly Val Ile Gly Asn Asn Leu Pro Ser Arg Ser 1 5 10 15 Asp Val Val Gln Leu Tyr Arg Ser Lys Gly Ile Asn Gly Met Arg Ile 20 25 30 Tyr Phe Ala Asp Gly Gln Ala Leu Ser Ala Leu Arg Asn Ser Gly Ile 35 40 45 Gly Leu Ile Leu Asp Ile Gly Asn Asp Gln Leu Ala Asn Ile Ala Ala 50 55 60 Ser Thr Ser Asn Ala Ala Ser Trp Val Gln Asn Asn Val Gln Pro Tyr 65 70 75 80 Tyr Pro Ala Val Asn Ile Lys Tyr Ile Ala Ala Gly Asn Glu Val Gln 85 90 95 Gly Gly Ala Thr Gln Ser Ile Leu Pro Ala Met Arg Asn Leu Asn Ala 100 105 110 Ala Leu Ser Ala Ala Gly Leu Gly Ala Ile Lys Val Ser Thr Ser Ile 115 120 125 Arg Phe Asp Glu Val Ala Asn Ser Phe Pro Pro Ser Ala Gly Val Phe 130 135 140 Lys Asn Ala Tyr Met Thr Asp Val Ala Arg Leu Leu Ala Ser Thr Gly 145 150 155 160 Ala Pro Leu Leu Ala Asn Val Tyr Pro Tyr Phe Ala Tyr Arg Asp Asn 165 170 175 Pro Gly Ser Ile Ser Leu Asn Tyr Ala Thr Phe Gln Pro Gly Thr Thr 180 185 190 Val Arg Asp Gln Asn Asn Gly Leu Thr Tyr Thr Ser Leu Phe Asp Ala 195 200 205 Met Val Asp Ala Val Tyr Ala Ala Leu Glu Lys Ala Gly Ala Pro Ala 210 215 220 Val Lys Val Val Val Ser Glu Ser Gly Trp Pro Ser Ala Gly Gly Phe 225 230 235 240 Ala Ala Ser Ala Gly Asn Ala Arg Thr Tyr Asn Gln Gly Leu Ile Asn 245 250 255 His Val Gly Gly Gly Thr Pro Lys Lys Arg Glu Ala Leu Glu Thr Tyr 260 265 270 Ile Phe Ala Met Phe Asn Glu Asn Gln Lys Thr Gly Asp Ala Thr Glu 275 280 285 Arg Ser Phe Gly Leu Phe Asn Pro Asp Lys Ser Pro Ala Tyr Asn Ile 290 295 300 Gln Phe 305 306 amino acids amino acid <Unknown> linear protein 8 Ile Gly Val Cys Tyr Gly Met Ser Ala Asn Asn Leu Pro Ala Ala Ser 1 5 10 15 Thr Val Val Ser Met Phe Lys Ser Asn Gly Ile Lys Ser Met Arg Leu 20 25 30 Tyr Ala Pro Asn Gln Ala Ala Leu Gln Ala Val Gly Gly Thr Gly Ile 35 40 45 Asn Val Val Val Gly Ala Pro Asn Asp Val Leu Ser Asn Leu Ala Ala 50 55 60 Ser Pro Ala Ala Ala Ala Ser Trp Val Lys Ser Asn Ile Gln Ala Tyr 65 70 75 80 Pro Lys Val Ser Phe Arg Tyr Val Cys Val Gly Asn Glu Val Ala Gly 85 90 95 Gly Ala Thr Arg Asn Leu Val Pro Ala Met Lys Asn Val His Gly Ala 100 105 110 Leu Val Ala Ala Gly Leu Gly His Ile Lys Val Thr Thr Ser Val Ser 115 120 125 Gln Ala Ile Leu Gly Val Phe Ser Pro Pro Ser Ala Gly Ser Phe Thr 130 135 140 Gly Glu Ala Ala Ala Phe Met Gly Pro Val Val Gln Phe Leu Ala Arg 145 150 155 160 Thr Asn Ala Pro Leu Met Ala Asn Ile Tyr Pro Tyr Leu Ala Trp Ala 165 170 175 Tyr Asn Pro Ser Ala Met Asp Met Gly Tyr Ala Leu Phe Asn Ala Ser 180 185 190 Gly Thr Val Val Arg Asp Gly Ala Tyr Gly Tyr Gln Asn Leu Phe Asp 195 200 205 Thr Thr Val Asp Ala Phe Tyr Thr Ala Met Gly Lys His Gly Gly Ser 210 215 220 Ser Val Lys Leu Val Val Ser Glu Ser Gly Trp Pro Ser Gly Gly Gly 225 230 235 240 Thr Ala Ala Thr Pro Ala Asn Ala Arg Phe Tyr Asn Gln His Leu Ile 245 250 255 Asn His Val Gly Arg Gly Thr Pro Arg His Pro Gly Ala Ile Glu Thr 260 265 270 Tyr Ile Phe Ala Met Phe Asn Glu Asn Gln Lys Asp Ser Gly Val Glu 275 280 285 Gln Asn Trp Gly Leu Phe Tyr Pro Asn Met Gln His Val Tyr Pro Ile 290 295 300 Asn Phe 305
Claims (22)
1. A plant (1→3,1→4)-β-glucanase enzyme of enhanced thermostability and/or pH stability, said enzyme being modified by transfer of a non-homologous protein sequence of different substrate specificity.
2. A plant (1→3,1→4)-β-glucanase in which the amino acid sequence of said enzyme:
(a) is modified to comprise structural elements of plant (1→3)-β-glucanase, said structural elements conferring improved heat stability;
(b) is modified at sites other than the active site to stabilise helices, to increase binding energy of the folded protein, to increase hydrogen bonding, and/or to prevent glycation; or
(c) is modified by creating cysteine pairs which can form disulphide bonds across the C and N terminals.
3. A (1→3,1→4)-β-glucanase according to claim 2 , in which two or more of the modifications (a) to (c) are present.
4. A (1→3,1→4)-β-glucanase according to claim 1 comprising the structural framework of the enzyme (1→3)-β-glucanase and elements of the catalytic site of (1→3,1→4)-β-glucanase.
5. An enzyme according to claim 4 additionally comprising modification (b) and/or modification (c) of claim 2 .
6. A (1→3,1→4)-β-glucanase according to claim 1 , in which the amino acid sequence of (1→3,1→4)-β-glucanase isoenzyme EII is modified to comprise one or more substitutions selected from the group consisting of:
Ala 15 Arg and Asn 36 Asp
Thr 17 Asp and Met 298 Lys
Ala 95 Asp and Ser 128 Arg
Pro 153 Asp and Gln 156 Arg
Lys 227 Arg and Gly 268 Arg
Gly 152 Thr and His 221 Ala.
Ala 14 Ser
Ala 15 Arg
Thr 17 Asp
Lys 23 Arg
Lys 28 Arg
Asn 36 Asp
Gly 44 Arg
Gly 45 Asn
Gly 53 Asp
Gly 53 Glu
Lys 74 Arg
Gln 78 Arg
Ala 79 Pro
Lys 82 Arg
Ala 95 Asp
Gly 97 Pro
Phe 85 Tyr
Lys 107 Arg
Gly 111 Ala
Gly 119 Pro
Lys 122 Arg
Ser 128 Arg
Gly 133 Ala
Gly 145 Asn
Gly 152 Thr
Pro 153 Asp
Gln 156 Arg
Asn 162 Gly
Gly 185 Asn
Ala 191 Pro
Gly 193 Ala
Gly 199 Pro
Ala 200 Gly
Gly 202 Thr
Gly 219 Glu
Lys 220 Arg
His 221 Ala
Gly 223 Ala
Ser 224 Pro
Lys 227 Arg
Gly 238 Ala
Gly 239 Gln
Ala 242 Gly
Gly 260 Glu
Pro 267 Arg
Gly 268 Glu
Gly 286 Ala
Gly 286 Asp
Gln 289 Arg
Met 298 Lys
His 300 Pro
subject to the proviso that the following ion pairs must both be substituted:
7. A (1→3,1→4)-β-glucanase according to claim 4 in which amino acids in the loops forming the sides and bottom of the active site cleft of (1→3)-β-glucanase GII are replaced by corresponding amino acids from (1→3,1→4)-β-glucanase EII, as follows:
residue 171-179 Phe-Ala-Tyr-Arg-Asp-Asn-Pro-Gly-Ser→Leu-Ala-Trp-Ala-Tyr-Asn-Pro-Ser-Ala (SEQ. ID NO: 2) and
residue 283-291 Thr-Gly-Asp-Ala-Thr-Glu-Arg-Ser-Phe→Asp-Ser-Gly-Val-Glu-Gln-Asn-Trp (SEQ. ID NO: 3)
8. A (1→3,1→4)-β-glucanase according to claim 6 comprising one or more of the following substitutions:
Gly 53 Asp
Gly 53 Glu
Thr 17 Asp; Met 298 Lys
Ala 95 Asp; Ser 128 Arg
Lys 122 Arg
Lys 23 Arg
Lys 74 Arg
Gly 44 Arg
Gly 223 Ala
Ala 89 Pro
Phe 85 Tyr
9. A (1→3,1→4)-β-glucanase according to any one of claims 6 to 8 , additionally comprising the mutation 189-191 Gln-Pro-Gly-→Asn-Ala-Ser.
10. A (1→3,1→4)-β-glucanase according to claim 6 comprising the substitution Lys 122→Arg and/or the substitution Phe 85→Tyr.
11. A DNA molecule whose sequence encodes a (1→3,1→4)-β-glucanase according to any one of claims 1 to 10 .
12. A plasmid comprising a DNA sequence according to claim 11 .
13. An expression vector comprising a DNA sequence according to claim 11 .
14. A transgenic plant comprising a DNA sequence according to claim 11 .
15. A transgenic plant according to claim 14 , selected from the group consisting of barley, wheat, rice, and maize.
16. A transgenic plant according to claim 15 , which is barley.
17. A process selected from the group consisting of malting, brewing and stockfeed processing, comprising the step of:
(a) using barley expressing the (1→3,1→4)-β-glucanase of any one of claims 1 to 10 as a starting material; or
(b) adding the (1→3,1→4)-β-glucanase of any one of claims 1 to 10 to a grain to be processed.
18. A composition for use in malting, brewing, or stockfeed processing, comprising the (1→3,1→4)-β-glucanase of any one of claims 1 to 10 , together with a carrier acceptable for use in processing of beverages or of stockfeeds.
19. A beverage produced using a composition according to claim 18 .
20. A stockfeed produced using a composition according to claim 18 .
21. Grain produced by a transgenic plant according to claim 15 .
22. Barley grain produced by a transgenic barley according to claim 16.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/785,246 US20030177530A1 (en) | 1993-07-07 | 2001-02-20 | (1 -> 3, 1 -> 4)-beta-glucanase of enhanced stability |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPL9821 | 1993-07-07 | ||
AUPL982193 | 1993-07-07 | ||
PCT/AU1994/000377 WO1995002042A1 (en) | 1993-07-07 | 1994-07-06 | (1 → 3, 1 → 4)-β-GLUCANASE OF ENHANCED STABILITY |
US08/584,008 US6277615B1 (en) | 1993-07-07 | 1996-01-11 | (1→3, 1→4)—β-glucanase of enhanced stability |
US09/785,246 US20030177530A1 (en) | 1993-07-07 | 2001-02-20 | (1 -> 3, 1 -> 4)-beta-glucanase of enhanced stability |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/584,008 Continuation US6277615B1 (en) | 1993-07-07 | 1996-01-11 | (1→3, 1→4)—β-glucanase of enhanced stability |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030177530A1 true US20030177530A1 (en) | 2003-09-18 |
Family
ID=3777041
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/584,008 Expired - Fee Related US6277615B1 (en) | 1993-07-07 | 1996-01-11 | (1→3, 1→4)—β-glucanase of enhanced stability |
US09/785,246 Abandoned US20030177530A1 (en) | 1993-07-07 | 2001-02-20 | (1 -> 3, 1 -> 4)-beta-glucanase of enhanced stability |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/584,008 Expired - Fee Related US6277615B1 (en) | 1993-07-07 | 1996-01-11 | (1→3, 1→4)—β-glucanase of enhanced stability |
Country Status (5)
Country | Link |
---|---|
US (2) | US6277615B1 (en) |
EP (1) | EP0707640A4 (en) |
JP (1) | JPH09500270A (en) |
CA (1) | CA2166777A1 (en) |
WO (1) | WO1995002042A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012036810A3 (en) * | 2010-09-15 | 2012-07-05 | The Regents Of The University Of California | Thermophilic mutants of trichoderma reesei endoglucanase i |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09500270A (en) * | 1993-07-07 | 1997-01-14 | バイオモレキュラー リサーチ インスティテュート リミティド | (1 → 3,1 → 4) -β-glucanase with enhanced stability |
CZ209397A3 (en) * | 1995-11-07 | 1998-03-18 | Gist-Brocades B. V. | Stable composition containing transgenic vegetable material |
AU1097297A (en) * | 1995-11-27 | 1997-06-19 | Gist-Brocades B.V. | Improved process for the production of semi-synthetic cephalosporins via expandase activity on penicillin |
DE69733759T2 (en) * | 1996-09-12 | 2006-03-30 | Syngenta Participations Ag | Cellulolytic enzyme-expressing transgenic plants |
CA2265914C (en) | 1996-09-17 | 2011-05-03 | Novo Nordisk A/S | Cellulase variants |
AU7908898A (en) * | 1997-07-04 | 1999-01-25 | Novo Nordisk A/S | Family 6 endo-1,4-beta-glucanase variants and cleaning composit ions containing them |
WO2001059141A2 (en) * | 2000-02-10 | 2001-08-16 | Washington State University Research Foundation | Methods and compositions that utilize barley as a foodstuff for animals |
JP4685294B2 (en) * | 2001-09-18 | 2011-05-18 | 株式会社カネカ | Novel peptide, production method, novel adsorbent, adsorber and adsorption method |
US20160289653A1 (en) | 2013-11-14 | 2016-10-06 | Danisco Us Inc. | Stable Enzymes by Glycation Reduction |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD272102B5 (en) * | 1988-05-12 | 1998-10-01 | Inst Pflanzengenetik & Kultur | Process for the preparation of thermostable Bacillus beta-1,3-1,4-glucanase |
DD275704A1 (en) * | 1988-09-23 | 1990-01-31 | Akad Wissenschaften Ddr | PROCESS FOR PRODUCING BARLEY PLANTS |
AU638695B2 (en) * | 1989-02-16 | 1993-07-08 | Akademie Der Wissenschaften Der Ddr | A thermostable (1,3-1,4)-beta-glucanase |
WO1992005258A1 (en) * | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
JPH09500270A (en) * | 1993-07-07 | 1997-01-14 | バイオモレキュラー リサーチ インスティテュート リミティド | (1 → 3,1 → 4) -β-glucanase with enhanced stability |
-
1994
- 1994-07-06 JP JP7503716A patent/JPH09500270A/en active Pending
- 1994-07-06 WO PCT/AU1994/000377 patent/WO1995002042A1/en not_active Application Discontinuation
- 1994-07-06 CA CA002166777A patent/CA2166777A1/en not_active Abandoned
- 1994-07-06 EP EP94920335A patent/EP0707640A4/en not_active Withdrawn
-
1996
- 1996-01-11 US US08/584,008 patent/US6277615B1/en not_active Expired - Fee Related
-
2001
- 2001-02-20 US US09/785,246 patent/US20030177530A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012036810A3 (en) * | 2010-09-15 | 2012-07-05 | The Regents Of The University Of California | Thermophilic mutants of trichoderma reesei endoglucanase i |
US9410135B2 (en) | 2010-09-15 | 2016-08-09 | The Regents Of The University Of California | Thermophilic mutants of Trichoderma reesei endoglucanase I |
Also Published As
Publication number | Publication date |
---|---|
JPH09500270A (en) | 1997-01-14 |
EP0707640A4 (en) | 2000-10-11 |
US6277615B1 (en) | 2001-08-21 |
WO1995002042A1 (en) | 1995-01-19 |
CA2166777A1 (en) | 1995-01-19 |
EP0707640A1 (en) | 1996-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104774823B (en) | Protease variants | |
AU717055B2 (en) | Tissue-specific promoter | |
JP2010154865A (en) | Glucoamylase variant | |
CN101550410A (en) | Glucoamylase variant | |
JP2530942B2 (en) | Enzyme improvements | |
US6277615B1 (en) | (1→3, 1→4)—β-glucanase of enhanced stability | |
CN101310016A (en) | Glucoamylase variants | |
US6329186B1 (en) | Glucoamylases with N-terminal extensions | |
Shibuya et al. | Construction of an α-amylase/glucoamylase fusion gene and its expression in Saccharomyces cerevisiae | |
US11873470B2 (en) | Brewing method | |
Klein et al. | Purification and characterization of invertase from a novel industrial yeast, Schwanniomyces occidentalis | |
CN112912504B (en) | Maltotriose-producing amylase | |
JP2000333684A (en) | Polypeptide having glucose isomerase activity and nucleic acid encoding the same | |
JP2002531121A (en) | Glucoamylase having N-terminal extension | |
JP2007312790A (en) | Α-1,4-glucan lyase from fungi, its purification, gene cloning and expression in microorganisms | |
BR112020018530A2 (en) | YEAST EXPRESSING THERMOSTABLE ALPHA-AMYLASES FOR STARCH HYDROLYSIS | |
JP2003210182A (en) | Thermophilic endoglucanase | |
US6506592B1 (en) | Hyperthermophilic alpha-glucosidase gene and its use | |
AU687415B2 (en) | (1 -> 3, 1 -> 4)-beta-glucanase of enhanced stability | |
US6222028B1 (en) | Polynucleotides encoding cellulase enzymes from Piromyces rhizinflata | |
Yin et al. | Amylase, β‐Glucanase and Protease Activities from a Mutant of Bacillus subtilis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |